Steatohepatitis is an advanced stage liver dysfunction associated with steatotic liver disease. In an interview with HT lifestyle, Dr. Rohit Mehtani, assistant professor, Department of Hepatology ...

North America is anticipated to provide a significant share of non-alcoholic steatohepatitis therapeWilmington, Delaware, United States, July 07, 2023 (GLOBE NEWSWIRE) -- The global non-alcoholic ...

Non-alcoholic steatohepatitis (NASH) is a condition characterized by accumulation of fat, inflammation and injury in liver cells in people who consume little or no alcohol. It is the progressive ...

The Business Research Company's Non-Alcoholic Steatohepatitis treatment Global market Report 2024 – Market Size, Trends, And Global Forecast 2024-2033 It will grow to $9.89 billion in 2028 at a ...

Non-alcoholic steatohepatitis (NASH) is a condition that falls under the umbrella of non-alcoholic fatty liver diseases. About 12 percent of the population in the United States is affected by NASH, ...

The non-alcoholic steatohepatitis (NASH) clinical trials market is estimated to generate a market size of USD 2.96 billion in ...

According to Prophecy Market Insights "Non-Alcoholic Steatohepatitis Biomarkers Market accounted for US$ 556.6 billion in 2019 and is estimated to be US$ 8177.9 billion by 2029 and is anticipated ...

Non-alcoholic steatohepatitis often occurs in individuals with metabolic risk factors like obesity, type 2 diabetes, hypothyroidism, deranged lipid profile or raised blood pressure.